Anti-CCP and RF: Drugs That Can Distort These Tests

What Anti-CCP and RF Actually Measure

Anti-cyclic citrullinated peptide (anti-CCP) antibodies target citrullinated proteins in joint tissue. RF is an autoantibody, usually IgM class, directed against the Fc portion of IgG. Both appear in the 2010 ACR/EULAR classification criteria for rheumatoid arthritis, where high-positive results (defined as greater than three times the upper limit of normal) score the maximum 3 points toward an RA diagnosis 1.

The two tests serve different diagnostic roles. A 2007 meta-analysis in Annals of Internal Medicine (54 studies, N=15,286) reported anti-CCP sensitivity of 67% and specificity of 95% for RA 2. RF, by contrast, is more sensitive (69 to 85%) but far less specific (60 to 70%), because it turns positive in hepatitis C, Sjogren syndrome, endocarditis, and even in 5 to 10% of healthy older adults 3.

This asymmetry matters when medications enter the picture. Drugs that lower RF may look like a treatment win but could simply be modifying the antibody without changing joint inflammation. Drugs that produce false-positive RF can trigger unnecessary rheumatology referrals. Anti-CCP is more stable on therapy, yet it is not immune to assay-level interference.

Biologics That Suppress RF Without Necessarily Suppressing Disease

Rituximab delivers the most dramatic RF changes of any biologic. A study by Cambridge and colleagues in Arthritis & Rheumatism (N=41 RA patients) showed that two infusions of rituximab 1 to 000 mg reduced median RF by 55% at 6 months 4. Anti-CCP levels dropped too, but only by 10 to 18%. The disconnect is instructive: rituximab depletes CD20-positive B cells that produce RF, yet the longer-lived plasma cells generating anti-CCP are relatively spared.

TNF inhibitors (infliximab, adalimumab, etanercept) can also reduce RF. De Rycke and colleagues reported in Annals of the Rheumatic Diseases that infliximab combined with methotrexate lowered IgM-RF by a median of 50% over 30 weeks in responders, while non-responders showed no significant decline 5. This makes RF monitoring less reliable as a disease-activity surrogate in patients on TNF blockers. A falling RF titer in a patient receiving infliximab could reflect true immunologic improvement or simply drug-mediated class switching.

Dr. Paul Emery, Professor of Rheumatology at the University of Leeds, has noted: "RF changes on biologics track with B-cell depletion more than with clinical response. Clinicians should never use RF trajectory alone to judge whether a biologic is working" 4.

Tocilizumab (IL-6 receptor blockade) adds a different wrinkle. By suppressing CRP and acute-phase reactants, it can mask inflammatory signals that usually run in parallel with RF. A clinician seeing a low CRP and declining RF in a patient on tocilizumab might conclude RA is quiescent when synovitis persists on ultrasound 6.

DMARDs That Gradually Lower RF Titers

Methotrexate, the anchor DMARD for RA, reduces RF over time in most responders. The BeSt study (N=508) documented meaningful RF declines across all four treatment arms, with the steepest drops in groups receiving early combination therapy including methotrexate 7. Anti-CCP levels remained more stable than RF across all arms, declining modestly (5 to 15%) over 2 years.

Leflunomide behaves similarly. A randomized trial comparing leflunomide to methotrexate (N=482 to 52 weeks) found both drugs reduced RF by roughly 30 to 40% in responders, with no statistically significant difference between them 8.

Sulfasalazine and hydroxychloroquine exert smaller, less consistent effects on RF. Their main relevance to test distortion is indirect: when combined with methotrexate in triple therapy, the aggregate RF decline may exceed what any single DMARD produces, making serial RF monitoring unreliable for attributing improvement to a specific drug.

The clinical takeaway is straightforward. If a patient's RF drops from 120 IU/mL to 40 IU/mL after 6 months of methotrexate, that decline probably reflects genuine immunomodulation. But it does not prove that joint erosion has stopped. The 2015 ACR guideline for RA management recommends imaging and composite disease-activity scores (DAS28, CDAI) over serial autoantibody titers for treatment decisions 9.

Drugs and Supplements That Cause False-Positive RF

RF false positives are surprisingly common. Any process that generates large immune complexes or polyclonal B-cell activation can push RF above the cutoff.

Hepatitis C treatment context. Chronic hepatitis C infection itself causes RF positivity in 40 to 76% of patients due to cryoglobulinemia 10. The older interferon-alfa regimens sometimes amplified this positivity transiently before viral clearance drove RF down. Direct-acting antivirals (sofosbuvir, ledipasvir, glecaprevir/pibrentasvir) clear the virus within 8 to 12 weeks, after which RF typically normalizes over 3 to 6 months. A patient tested during early treatment may show persistently elevated RF that does not indicate RA.

Checkpoint inhibitors. Immune checkpoint blockade (nivolumab, pembrolizumab, ipilimumab) can trigger de novo autoantibody production, including RF and occasionally anti-CCP. A 2019 review in The Lancet Oncology identified inflammatory arthritis in 2 to 5% of patients on checkpoint inhibitors, with RF positivity in a subset 11. These drug-induced antibodies can persist for months after the checkpoint inhibitor is discontinued.

Other notable culprits. Isoniazid, procainamide, and hydralazine are established triggers of drug-induced lupus and can generate RF positivity. IV immunoglobulin (IVIG) introduces exogenous IgG that saturates anti-IgG assays, creating transient false-positive RF readings that resolve within 4 to 6 weeks after infusion.

Biotin: The Supplement That Corrupts Both Assays

Biotin (vitamin B7) deserves its own section because its interference mechanism differs from every drug listed above. Biotin does not change antibody levels. It corrupts the assay chemistry itself.

Many modern immunoassays, including platforms from Roche and Siemens, use streptavidin-biotin binding as an anchor step. When circulating biotin from oral supplements competes with the assay's biotin-labeled reagents, results shift unpredictably. The FDA issued a safety communication in November 2017 warning that biotin at doses above 5 mg/day can cause "falsely high or falsely low results" depending on assay design 12.

For competitive assays (used by some RF platforms), biotin interference produces falsely elevated results. For sandwich assays (used by most anti-CCP platforms), it produces falsely low results. This means a single patient taking high-dose biotin could simultaneously show a false-positive RF and a false-negative anti-CCP, mimicking seronegative RA or dismissing true seropositive disease.

The 2010 ACR/EULAR criteria assign zero points for negative anti-CCP. A biotin-suppressed anti-CCP could downgrade a patient's classification score below the diagnostic threshold of 6 points, delaying treatment by months.

Practical threshold: doses at or below 2.5 mg/day (found in most standard multivitamins) are unlikely to interfere. Doses of 5 to 10 mg/day, commonly sold for hair and nail growth, are within the interference range. Doses of 100 to 300 mg/day, used in multiple sclerosis trials, will almost certainly corrupt streptavidin-biotin assays 12.

The fix is simple. Stop biotin at least 72 hours before blood draw. Some labs now add biotin-stripping reagents to their platforms, but coverage is not universal.

How to Time Labs Around Medication Use

Timing matters more than most clinicians realize. Drawing RF or anti-CCP at the wrong point in a drug cycle can yield a number that misleads rather than informs.

Rituximab. The nadir for RF occurs at approximately 6 months post-infusion, coinciding with peak B-cell depletion. If RF monitoring is clinically needed, draw at a consistent interval relative to the infusion cycle (typically immediately before re-dosing at 6 months) rather than at arbitrary time points 4.

TNF inhibitors. RF fluctuations track loosely with trough drug levels. For patients on every-other-week adalimumab, drawing labs on the day of injection (trough) provides the most reproducible baseline. Mid-cycle draws may show transiently lower RF.

Biotin. The FDA recommends a minimum 72-hour washout. For patients on very high doses (100+ mg/day), some laboratory medicine specialists recommend 7 days 12.

IVIG. Wait at least 4 weeks after the last infusion before interpreting RF results. Anti-CCP is less affected but may still show mild interference on certain platforms.

Checkpoint inhibitors. Baseline RF and anti-CCP before initiating immunotherapy provides a reference point. Any subsequent rise can then be attributed to the drug rather than mistaken for pre-existing autoimmunity.

The American College of Rheumatology's 2010 classification criteria document states: "Serologic testing should be performed at the time of initial evaluation, ideally before immunomodulatory therapy is initiated, to establish baseline autoantibody status" 1.

Normal Ranges and How to Interpret Drug-Affected Results

Standard reference ranges for anti-CCP and RF vary by laboratory platform, but general thresholds are well established.

Anti-CCP (second-generation, CCP2 assay). Negative: <20 U/mL. Low positive: 20 to 39 U/mL. Moderate positive: 40 to 59 U/mL. High positive (strongly suggestive of RA): 60 U/mL and above. Under the 2010 ACR/EULAR criteria, "high positive" is defined as greater than three times the upper limit of normal 1.

Rheumatoid factor (nephelometry). Negative: <14 IU/mL. Low positive: 14 to 42 IU/mL. High positive: greater than 42 IU/mL. Some labs use <20 IU/mL as the cutoff. Always reference the reporting lab's specific range.

When a patient is on a drug known to suppress RF, interpretation requires context. A patient on rituximab with an RF of 18 IU/mL (technically "low positive") may have had a pre-treatment RF of 200 IU/mL. That 91% decline reflects B-cell depletion, not disease remission or a near-normal immune state. Comparing the current value against the pre-treatment baseline is more informative than comparing it against the reference range 7.

Anti-CCP is less susceptible to drug-induced suppression, which is one reason some rheumatologists treat it as the more trustworthy long-term marker. A patient who was anti-CCP positive at diagnosis will almost always remain anti-CCP positive even after years of effective DMARD therapy. Seroconversion from positive to negative does occur, but it is rare (estimated at 5 to 12% over 5 years) and is more commonly associated with rituximab than with any other agent 4.

For patients whose RF or anti-CCP results seem inconsistent with their clinical picture, the most efficient next step is to re-draw labs after controlling for the interfering variable: stop biotin, time the draw relative to the biologic cycle, or repeat the test on an alternative assay platform that uses a different detection chemistry.